Deal Watch: Sanofi And Evotec Negotiate Alliance Aimed At Improving Drug Discovery
Executive Summary
Janssen licenses a rheumatoid arthritis program from Modern Biosciences that could address the inflammatory and bone-destruction manifestations of the disease, while Japan’s Otsuka buys Avanir on the strength of its neuroscience pipeline. Meanwhile, previously signed Astellas/Janssen and Novartis/Array agreements are terminated.
You may also be interested in...
U.S. Approval, Sales Milestones Could Double PneumRx Price For BTG
Contingency payments based on regulatory and sales milestones for lead emphysema product RePneu could double the price BTG pays for U.S. biotech PneumRx, the latest addition to the U.K. company’s interventional medicines business.
J&J Sprouts New Innovation Centers In Industry Hot Spots
In an effort to expand outreach to and interaction with innovation-rich communities, J&J is creating four new regional innovation centers to act as scouts, deal-makers and alliance managers in Shanghai, Boston, California and London.
Lilly Gains New Indication For Forteo, But Also A REMS And Patient Registry
Lilly is setting up a voluntary Forteo patient registry to collect data on potential bone cancer risk as part of FDA's approval of a new indication for the osteoporosis treatment. The company is also instituting a Risk Evaluation and Mitigation Strategy to control for the risk